Covaxin booster dose neutralises Omicron and Delta, says Bharat Biotech

Vaccine manufacturer Bharat Biotech said the booster dose of Covaxin has generated robust neutralising antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2), using a live virus neutralisation assay.

Test results show that 100 per cent of the serum samples showed neutralisation of the Delta variant and more than 90% of serum samples showed neutralisation of the Omicron variant, Bharat Biotech said.

In a statement, the vaccine manufacturer announced results from a study conducted at Emory



University, demonstrating that sera from subjects, who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin® (BBV152), neutralised the SARS-CoV-2 Omicron and Delta variants.

Earlier, studies demonstrated the neutralising potential of Covaxin (BBV152) against SARS-CoV-2 variants of Concern Alpha, Beta, Delta, Zeta and Kappa.

The company said that based on emerging data, it believes that a third dose may be beneficial to maintain the highest levels of protection.